The post What happens when CEO Jamie Dimon leaves? appeared on BitcoinEthereumNews.com. As Wall Street’s top bankers huddled in New York last month, preparing toThe post What happens when CEO Jamie Dimon leaves? appeared on BitcoinEthereumNews.com. As Wall Street’s top bankers huddled in New York last month, preparing to

What happens when CEO Jamie Dimon leaves?

As Wall Street’s top bankers huddled in New York last month, preparing to convince Elon Musk’s SpaceX that they should be chosen to lead its upcoming IPO, one firm wasn’t letting its star advisor miss the bake-off.

Among the squad of JPMorgan Chase investment bankers flying 2,500 miles west to California to pitch SpaceX was the lender’s boss, billionaire CEO Jamie Dimon, people with knowledge of the trip told CNBC.

The morning after that pitch meeting, on Dec. 19, Dimon was already back in his customary early Friday perch: sitting in his bank’s New York lobby, taking meetings in full view of the thousands of employees streaming through the building’s turnstiles.

The whirlwind few days highlight the reality of Dimon’s singular impact on JPMorgan, the world’s largest bank by market capitalization.

Dimon marks his 20th anniversary as CEO this month and remains deeply involved across the sprawling businesses of JPMorgan, a giant across Wall Street and Main Street with $4.6 trillion in assets. Half a dozen executives across investment banking, asset management and consumer banking echoed that view.

Which makes the inevitable questions surrounding Dimon’s tenure loom large as he approaches 70 years of age. Dimon has for years maintained, somewhat tongue-in-cheek, that his retirement was perpetually 5 years away. In 2024, for the first time, he acknowledged that window was shrinking.

Will JPMorgan’s era of dominance be over when Dimon exits as CEO?

“Given his track record, anybody else would be a downgrade,” said Ben Mackovak, a bank board member and investor through his firm Strategic Value Bank Partners.

“I’m sure somebody else could grow into the role and surprise people,” Mackovak said. “But on day one, no one is going to be as qualified to run that bank as Jamie.”

Jamie Dimon, Chairman and Chief Executive Officer of JPMorgan Chase & Co., attends the ribbon-cutting ceremony opening the firm’s new headquarters at 270 Park Avenue, in New York City, U.S., October 21, 2025.

Eduardo Munoz | Reuters

In two decades, Dimon took a middle-of-the-pack American lender and, with his unique combination of judgment, paranoia, attention to detail and scope of vision, created a juggernaut of finance that the world hadn’t seen before.

During calm times, he invested aggressively for the future, and during periods of tumult, like 2008 and 2023, he avoided pitfalls that consumed other banks, allowing him to snap up three failed institutions.

Over the past 20 years, the bank’s annual net income soared more than 500% to $58.5 billion in 2024. The firm reports full-year 2025 results on Tuesday.

Now, at a market cap of roughly $900 billion, JPMorgan is worth nearly as much as the next three largest U.S. banks combined: Bank of America, Citigroup and Wells Fargo.

Besides running JPMorgan, Dimon has taken on an outsized role in global finance as a top voice explaining market gyrations or emerging risks and influencing regulators amid policy shifts. It was Dimon’s recession warning on a Fox News segment in April that helped convince President Donald Trump to pivot on his trade policy, igniting a historic relief rally.

“It’s just the aura he has, the credibility that he’s built up in the markets,” said Fitch Ratings analyst Chris Wolfe. “The minute you step out of that role, it’s not like you can just hand that over, your successor doesn’t automatically inherit that. I think that’s the real challenge.”

Potential successors

The question of who could take over for Dimon — who was already a cancer survivor when he nearly died in 2020 from a ruptured aorta — has been openly discussed among investors for more than a decade.

To investors, his most likely successor is currently Marianne Lake, head of the firm’s giant consumer bank and former CFO of the company, followed by Doug Petno and Troy Rohrbaugh, the co-heads of the firm’s commercial and investment bank.

Marianne Lake, chief financial officer of JPMorgan Chase & Co.

Jin Lee | Bloomberg | Getty Images

Other contenders include asset and wealth management head Mary Erdoes and CFO Jeremy Barnum.

“If investors were to do a straw poll today, they’d probably pick Marianne,” said Truist bank analyst Brian Foran.

“The running joke is that she’s a human supercomputer when it comes to banking,” Foran said. “Really, the only question mark people have about her is, she’s so analytical, can she do the kind of ‘rah-rah’ stuff to inspire the sales force?”

Wells Fargo banking analyst Mike Mayo hypothesized that JPMorgan stock could immediately drop 5% if Dimon were to suddenly exit, regardless of the named replacement. (The bank has said Dimon would serve as chairman even after relinquishing the CEO role.)

It’s a somewhat common occurrence on Wall Street for companies with iconic CEOs: The stock premium shrinks, at least for a period, when their longtime leaders announce their departures. For instance, Berkshire Hathaway shares trailed the S&P 500 last year after Warren Buffett said he was stepping down as CEO.

‘Never going to quit’

When asked about CEO succession, JPMorgan executives say that Dimon is as plugged in as ever, and unlikely to step down soon.

Depending on how long he sticks around, that means it’s not necessarily his current direct reports like Lake, Petno and Rohrbaugh who are in line, but more junior executives now being groomed and evaluated for leadership roles, they told CNBC.

“There’s a lot of work going into imagining that day without him,” said a JPMorgan executive who asked not to be named speaking about his boss. “If he stays until he’s 85, it’s not his direct reports that are going to be next in line, its maybe one or two levels down from today.”

“Does he leave a huge vacuum? Yes,” said the executive. “It’s not fatal, though, because we’ve been planning for it. I think there’s combinations of people that together can create the same outcome.”

The CEO of a commercial bank and former JPMorgan executive, who described Dimon as a mentor, also said he didn’t think Dimon would step down soon.

“Jamie’s never going to quit,” said the CEO, who asked for anonymity to speak candidly. “What else would he do where he’s as important as he is now? His friends are all people from work. He loves it.”

Still, beyond the day-to-day management of a company with 318,000 employees, Dimon seems intent on setting up JPMorgan for a future without him.

Legacy values

In recent months, Dimon oversaw the completion of the bank’s new $3 billion headquarters in midtown Manhattan and announced a $1.5 trillion initiative to bolster industries crucial to U.S. interests.

And, perhaps most crucially, he continues to instill his values into the firm’s management team.

Last year, at a conference for JPMorgan’s top 400 executives, Dimon rattled off a list of once-great companies that died though mismanagement. Finance is especially prone to this threat, because of the temptation to manipulate numbers for short-term gain, he said.

“Travelers blew up. Citi blew up, twice. Bear Stearns failed, Lehman failed, I’m here because Bank One screwed up a bunch of businesses,” Dimon said, referring to a predecessor firm to JPMorgan.

“If you look at these things, it’s complacency, it’s bureaucracy, it’s arrogance. A lot of it is dishonest numbers. Failure to set standards,” Dimon said. “These are the cancers that kill companies.”

Nobody knows when Dimon’s last day as CEO will come, except to know that it is approaching. After adjusting his standard 5-year retirement answer to hint at a sooner departure, Dimon hasn’t advanced that clock any further.

“As great as he is, he can’t do this forever,” said Barclays banking analyst Jason Goldberg. “Every day that passes, you’re a day closer to the end.”

— CNBC’s Gabriel Cortes contributed to this report.

Source: https://www.cnbc.com/2026/01/12/jpmorgans-looming-question-what-happens-when-ceo-jamie-dimon-leaves.html

Market Opportunity
TOP Network Logo
TOP Network Price(TOP)
$0.000096
$0.000096$0.000096
0.00%
USD
TOP Network (TOP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26